dr. yetunde t. israel-aina paediatrician, university of benin teaching hospital, benin city benin...
TRANSCRIPT
![Page 1: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/1.jpg)
DR. YETUNDE T. ISRAEL-AINAPAEDIATRICIAN,
UNIVERSITY OF BENIN TEACHING HOSPITAL,BENIN CITY
BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN
CITY. JULY 15 – 27 , 2013 .
HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
LEUKAEMIA IN CHILDREN
![Page 2: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/2.jpg)
Overview
The spectrum and biological characteristics of
haematological malignancies are significantly
different between children and adults.
Questioning the applicability of transplant for any diagnosis is appropriate, especially in the field of paediatric leukaemia.
Improvements in survival of children with leukaemia: over 80% for standard risk ALL and 50-70% for AML
![Page 3: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/3.jpg)
Introduction
HSCT is reserved for high-risk leukaemia patients in first and subsequent remission who are unlikely to be cured by chemotherapy.
Identify high risk children with the knowledge of current outcome with chemotherapy, leukaemia biology and likely transplant outcomes
![Page 4: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/4.jpg)
How HSCT works in leukaemia
Transplant allows use of high doses of chemotherapeutic drugs to kill leukaemic cells.
Graft versus leukaemia effect (GvL): Alloreactive T-cells in the graft attack leukaemic cells in the recipient. Effect of GvL is seen more in CML than in AML and ALL.
Role of donor lymphocyte infusion (DLI)- survival at 2yrs greater in children who had DLI .
![Page 5: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/5.jpg)
ALL
Curable by first-line treatment in 80% of cases
EFS at 8 years is 75% for ALL patients
![Page 6: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/6.jpg)
Indications for transplant in ALL
CR1In high-risk children with ALL in CR1CR could not be achieved after initial induction therapy. Over 10-2 minimal residual disease (MRD) remains after
induction therapy, Ph+ chromosome or the Bcr-AbL fusion gene is positive. In infants aged less than one year with t (4:11) and the
MLL/AF4 fusion gene,WBC>100X109/L ≥CR2Intermediate and standard-risk ALL in ≥CR2 who relapsedless than 36 months after diagnosis.
![Page 7: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/7.jpg)
AML
With intensive chemotherapy, 80-90% achieve CR
30-70% are cured with post induction chemotherapy
45-64% long term survival in children with high risk AML in CR1 – using MRD transplant
Over 60% of children do not have MRD
Individual case assessment needed for transplant in children with AML
![Page 8: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/8.jpg)
Indications for transplant in AML
AML-High-risk acute myelogenous leukaemia (AML) includes M4, M5, M6, M7 subtypes in FAB classification
In CR1, Ph' chromosome (+) AML in CR1, 5q, 7q deletion in CR1, and Flt3-ITD mutation in CR1.
CR could not be achieved after one or two courses of standardized induction therapy.
The WBC count is over 100×109/L initially in CR1. CR2 AML or secondary AML due to MDS
transformationRelapsed AML with a suitable donorCR1 in treatment-related AML (t-AML). Chronic myelogenous leukaemia in chronic phase,
![Page 9: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/9.jpg)
MDS
Acct for < 5% of haematologic malignanciesVariants important for transplant- RAEB and RAEB-t- Juvenile myelomonocytic leukaemia JMMLJMML – median age at diagnosis is 2years - M: F= 2:1 - Allo-HSCT is the only cure, with long
term survival - age >4yrs and female sex predicted
poor outcome in transplanted children.
![Page 10: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/10.jpg)
Myeloablative conditioning
High-dose regimens are particularly useful in conditioning patients with aggressive malignancies.
Cyclophosphamide plus total body irradiation (TBI) or busulfan and cyclophosphamide are typical combinations for full myeloablative regimens.
![Page 11: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/11.jpg)
Reduced intensity conditioning - RIC
Reduced-intensity or non-myeloablative regimens use lower doses of pre-transplant chemotherapy drugs and/or radiation
These regimens do not completely eliminate malignant cells, but rely on graft-versus-malignancy effect mediated by donor-origin lymphoid cells, mostly T cells.
Reduced-intensity regimens use combinations of chemotherapy drugs such as fludarabine, busulfan, and melphalan, with or without low-dose radiation.
![Page 12: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/12.jpg)
Conditioning for malignant diseases
For ALL
1 . fTBI (fractionated total body irradiatin)
VP 16 (Etoposide) or Cyclophosphamide
2. Busulfan Cyclophosphamide
3. Clofarabin Busulfan
4. Busulfan Fludarabin Thiotepa
For AML/MDS/RAEB
Busulfan
Cyclophosphamide
Melphalan
![Page 13: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/13.jpg)
Type of transplant
Autologous - Used as consolidation
in high risk AML in CR1 or 2 without MRD.
- Auto-HSCT (with in-vitro purging) is not a valid alternative to multi-drug chemotherapy or to allo-HSCT
Allogeneic - Best option - Early allo-HSCT led
to better overall results than auto-HSCT
![Page 14: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/14.jpg)
Donor selection and stem cell source
MSD – still the gold standard. Available in only 25% of cases.
MUD – acceptableUnmanipulated bone marrow – standard for
MSD.PBSC – risk of GVHD T- cell depletion performed only in
mismatched donor.UCBT – acceptable outcome if sufficient dose
is infusedHaploidentical transplant
![Page 15: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/15.jpg)
Outcome
Transplants for acute leukaemias, ALL and AML, in remission at the time of transplant have survival rates of 55-68% if the donor is related and 26-50% if the donor is unrelated .
![Page 16: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/16.jpg)
Summary
HSCT with bone marrow source is the first choice .
Then, MRD with cord blood with sufficient dose, if lower UCB, supplement with BM from the sibling.
If above two are not available, MUD is indicated.
![Page 17: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/17.jpg)
References
Davies SM, Parinda M. Pediatric acute lymphoblastic leukaemia: is there still a role for transplant? American Society of Haematology Education Program. (asheducationbook.hem)
EBMT Handbook. Haematopoietic Stem Cell Transplantation. 6th ed. 2012.
![Page 18: DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN](https://reader036.vdocuments.mx/reader036/viewer/2022083004/56649e855503460f94b87c80/html5/thumbnails/18.jpg)
THANKS!!!